The GLP-1 booster market has exploded in 20252026, with brands positioning fiber, probiotic, and metabolic blends as "natural GLP-1" products
Shah says he would caution people with type 1 who are not overweight to avoid taking a GLP-1 drug, since retrospective studies have found that this group tends to have more gastrointestinal side effects, which may lead them to stop using the drug
The exact deadline can be complicated to determine, as it depends on when the injury occurred and when the patient reasonably should have known that the drug was the cause of the injury (the discovery rule)
Its safety and efficacy have not been determined
These may cost employees more than a standard insurance co-pay of $25, but are still generally less than employers pay for the drugs through pharmacy benefit managers
Semaglutide (Wegovy) has demonstrated cardiovascular risk reduction in clinical trials, reducing the risk of major cardiovascular events by 20%